Logo Logo

Zitation: Auernhammer, Christoph J und Wang, Katharina und Maccio, Umberto und Knösel, Thomas und Hungbauer, Maximilian P und Schilbach, Katharina und Maurer, Julian und Peischer, Lea und Reul, Astrid und Kuzmenko, Elena und Luca, Edlira und Hamati, Julia und Vetter, Diana und Oberholzer, Jose und Fritsch, Ralph und Pacak, Karel und Grossman, Ashley B und Beuschlein, Felix und Reincke, Martin und Hantel, Constanze und Zitzmann, Kathrin und Nölting, Svenja: Supplementary data: Personalized drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms. 30. Dezember 2025. Open Data LMU. 10.5282/ubm/data.747

Supplementary data: Personalized drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms
Supplementary data: Personalized drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms

This dataset contains supplementary material to the associated article “Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms”. The article was published in the Journal of Clinical Endocrinology and Metabolism.

Data to: Christoph J Auernhammer, Katharina Wang, Umberto Maccio, Thomas Knösel, Maximilian P Hungbauer, Katharina Schilbach, Julian Maurer, Lea Peischer, Astrid Reul, Elena Kuzmenko, Edlira Luca, Julia Hamati, Diana Vetter, Jose Oberholzer, Ralph Fritsch, Karel Pacak, Ashley B Grossman, Felix Beuschlein, Martin Reincke, Constanze Hantel, Kathrin Zitzmann, Svenja Nölting, Personalized drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms, The Journal of Clinical Endocrinology & Metabolism, 2026; https://doi.org/10.1210/clinem/dgaf705

neuroendocrine tumor, primary culture, precision medicine, personalized drug testing
Auernhammer, Christoph J
Wang, Katharina
Maccio, Umberto
Knösel, Thomas
Hungbauer, Maximilian P
Schilbach, Katharina
Maurer, Julian
Peischer, Lea
Reul, Astrid
Kuzmenko, Elena
Luca, Edlira
Hamati, Julia
Vetter, Diana
Oberholzer, Jose
Fritsch, Ralph
Pacak, Karel
Grossman, Ashley B
Beuschlein, Felix
Reincke, Martin
Hantel, Constanze
Zitzmann, Kathrin
Nölting, Svenja
2025

[thumbnail of Supplementary data: Personalized drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms]
Vorschau
PDF (Supplementary data: Personalized drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms)
Suppl Table.pdf - Ergänzendes Material

123kB

DOI: 10.5282/ubm/data.747

Dieser Datensatz steht unter der Creative Commons Lizenz
CC BY 4.0

Be­schrei­bung

This dataset contains supplementary material to the associated article “Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms”. The article was published in the Journal of Clinical Endocrinology and Metabolism. Data to: Christoph J Auernhammer, Katharina Wang, Umberto Maccio, Thomas Knösel, Maximilian P Hungbauer, Katharina Schilbach, Julian Maurer, Lea Peischer, Astrid Reul, Elena Kuzmenko, Edlira Luca, Julia Hamati, Diana Vetter, Jose Oberholzer, Ralph Fritsch, Karel Pacak, Ashley B Grossman, Felix Beuschlein, Martin Reincke, Constanze Hantel, Kathrin Zitzmann, Svenja Nölting, Personalized drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms, The Journal of Clinical Endocrinology & Metabolism, 2026; https://doi.org/10.1210/clinem/dgaf705

Stichwörter

neuroendocrine tumor, primary culture, precision medicine, personalized drug testing

Dokumententyp:Daten
Name der Kontakt­person:Wang, Katharina
E-Mail der Kontaktperson:K.Wang at med.uni-muenchen.de
Fächer:Medizin
Dewey Dezimal­klassi­fikation:600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
ID Code:747
Eingestellt von: Katharina Wang
Eingestellt am:09. Jan. 2026 15:10
Letzte Änderungen:12. Jan. 2026 08:18

Nur für Administratoren und Editoren: Dokument bearbeiten